2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy

Br J Haematol. 1996 May;93(2):409-11. doi: 10.1046/j.1365-2141.1996.5041045.x.

Abstract

We treated 26 patients with hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine, including nine with abdominal lymphadenopathy and of whom two had HCL-variant; 18 were previously treated. The overall response in 23 evaluable HCL patients was 100% with 87% complete remission (CR). The CR rate was 57% in patients with abdominal lymphadenopathy. Neither of the patients with HCL-variant achieved CR. Of four patients who had become refractory to 2'-deoxycoformycin, two achieved CR and one partial remission (PR). The lower response in HCL with abdominal lymphadenopathy supports the view that this represents a more resistant form of the disease.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Cladribine / therapeutic use*
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Hairy Cell / complications
  • Leukemia, Hairy Cell / drug therapy*
  • Lymphatic Diseases / complications*
  • Male
  • Middle Aged
  • Recurrence
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Cladribine